The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
Hungarian lab worker isolated after exposure to Ebola virus
on April 21, 2018 at 4:21 am
The World Health Organisation said it had sent an experimental vaccine and other treatments which had been given to the scientist. "WHO assesses the risk of Ebola spreading from this event negligible," it said in a statement emailed to Reuters. […]
Ebola Vaccine Market - Global Industry Insights, and Opportunity Analysis, 2025
on April 21, 2018 at 1:46 am
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola ... […]
Scientist accidentally exposed himself to ebola virus in Hungarian lab experiment gone wrong
on April 20, 2018 at 11:48 am
WORRIED World Health Organisation experts have sent a shipment of an experimental Ebola vaccine and drugs to treat a scientist who has been exposed to the deadly disease. The UN health agency revealed tonight that Hungarian officials asked for help after a ... […]
UN health agency: Hungarian scientist exposed to Ebola
on April 20, 2018 at 7:53 am
The World Health Organization says it has coordinated shipment of an experimental Ebola vaccine and drugs to treat a laboratory scientist in Hungary who was exposed to the potentially deadly disease earlier this month. The U.N. health agency said in an ... […]
Global Ebola vaccine market is expected to be driven by increasing vaccine development across the globe
on April 19, 2018 at 9:54 pm
Apr 20, 2018 (marketresearch.biz via COMTEX) -- Ebola vaccine is used against viral hemorrhagic fever that is causes due to Ebola virus disease. This disease initially spread from animals to human and later transmission started from human to human. […]
Ebola media coverage impacted how the public perceived the disease and survivors
on April 18, 2018 at 10:41 am
Co-authors of the study include Josh Barker, doctoral candidate at the University of North Carolina at Chapel Hill, and Mugur Geana, associate professor at the University of Kansas. Explore further: Would you pay for an Ebola vaccine? Most say yes. […]
Merck’s Ebola shot delivers antibodies that could last 2 years or more, study finds
on April 17, 2018 at 8:15 am
Previous studies have shown that Merck & Co.’s Ebola vaccine can act fast and can maintain an antibody response for at least one year. Now, a new study has doubled that estimate. The new study, published in Lancet Infectious Diseases, shows antibodies ... […]
In encouraging sign, Ebola vaccine appears to provide long-lasting protection
on April 16, 2018 at 1:53 am
n international consortium of researchers has reported that an Ebola vaccine appears to provide volunteers protection against the virus two years after they were injected — encouraging findings both for the public health community and the vaccine’s ... […]
Work on DNA Vaccines Still Has a Way to Go
on April 15, 2018 at 9:05 pm
That speed and flexibility in the DNA vaccine platform allows for rapid prototyping in response to emerging diseases. Dr. Weiner and his colleagues developed an Ebola vaccine in just 18 months. Dr. Mascola and his team were able to rapidly shift a DNA ... […]
via Google News and Bing News